Evidence map›Paper›PMID 42050050›Full record

ArticleCancer gene therapy2026

Preclinical development of a mutant KRAS targeting therapeutic cancer vaccine.

Catarina Pinto, Romana Bischl, Lea Knezevic, Sarah Ahmadi-Erber, Katell Bidet Huang, Sarah Schmidt, Peter Steinberger, Klaus K Orlinger, Henning Lauterbach, Josipa Raguz

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Catarina PintoHookipa Pharma Inc., New York, NY, USA.ORCID http://orcid.org/0000-0002-9021-7005
Romana BischlHookipa Pharma Inc., New York, NY, USA.
Lea KnezevicInstitute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0009-0005-3471-9624
Sarah Ahmadi-ErberHookipa Pharma Inc., New York, NY, USA.
Katell Bidet HuangHookipa Pharma Inc., New York, NY, USA.
Sarah SchmidtHookipa Pharma Inc., New York, NY, USA.
Peter SteinbergerInstitute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
Klaus K OrlingerHookipa Pharma Inc., New York, NY, USA.
Henning LauterbachHookipa Pharma Inc., New York, NY, USA.ORCID http://orcid.org/0000-0002-6062-5163
Josipa RaguzHookipa Pharma Inc., New York, NY, USA. josipa.raguz@hookipapharma.com.ORCID http://orcid.org/0000-0002-6416-0586

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

KRAS mutations are frequent oncogenic drivers in several indications, yet limited targeted therapy options are available. Here we engineered our clinically validated artARENA platform to develop an "off-the-shelf" shared neoantigen vaccine, capable of triggering potent CD8

Indexed as

Cancer VaccinesMutationNeoplasmsProto-Oncogene Proteins p21(ras)AnimalsCD8-Positive T-LymphocytesHumansMiceMice, TransgenicCancer VaccinesKRAS protein, humanProto-Oncogene Proteins p21(ras)

Identifiers

PMID42050050

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.